Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility
02 févr. 2022 07h00 HE
|
Tarsus Pharmaceuticals, Inc
Topline data expected in April 2022 from Saturn-2, the second Phase 3 pivotal trial of TP-03 and NDA submission remains on track for this year Credit facility with Hercules Capital and Silicon Valley...
Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors
04 janv. 2022 09h00 HE
|
Tarsus Pharmaceuticals, Inc
Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tarsus...
Tarsus to Participate at Upcoming Virtual Investor Conferences
23 nov. 2021 16h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021
10 nov. 2021 16h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements
09 nov. 2021 16h05 HE
|
Tarsus Pharmaceuticals, Inc
On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis; topline data expected in the first...
Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting
04 nov. 2021 09h45 HE
|
Tarsus Pharmaceuticals, Inc
Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups New Titan...
Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference
02 nov. 2021 17h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors
12 août 2021 09h00 HE
|
Tarsus Pharmaceuticals, Inc
Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries IRVINE, Calif., Aug. 12, 2021 ...
Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates
04 août 2021 17h30 HE
|
Tarsus Pharmaceuticals, Inc
Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery...
Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
24 juil. 2021 18h00 HE
|
Tarsus Pharmaceuticals, Inc
New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette...